论文部分内容阅读
抗体导向酶──前药疗法（ａｎｔｉｂｄｙ－ｄｉｒｅｃｔｅｄ ｅｎｚｙｍｅ ｐｒｏｄｒｕｇ ｔｈｅｒａｐｙ，ＡＤＥＰＴ）是利用抗体作为载体将前药的专一性活化酶选择性地结合于肿瘤部位，使无毒性的前药可以区域特异性地在肿瘤组织内转化为活性细胞毒分子，杀伤肿瘤。利用不同的活化酶／前药对已建立了多种ＡＤＥＰＴ系统，羧肽酶Ｇ２／ＭＭＣ１系统已用于临床Ⅰ期试验。本文就ＡＤＥＰＴ研究和应用的最新进展作一综述。
Antibdy-directed enzyme prodrug therapy (ADEPT) uses an antibody as a carrier to selectively bind a prodrug-specific activating enzyme to a tumor site so that a non-toxic prodrug may be region-specific. In the tumor tissue, it is transformed into active cytotoxic molecules that kill the tumor. A variety of ADEPT systems have been established using different activated enzyme/prodrug pairs. The carboxypeptidase G2/MMC1 system has been used in clinical Phase I trials. This article reviews recent advances in ADEPT research and applications.